Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.49 |
| ▸ | SLC6A11 | P48066 | 4/20 | 0.47 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3997667 | 0.90 | KIF11 (0.48) | KIF11SLC6A11SLC6A1KCNH2CA4 | |
| SCHEMBL28353747 | 0.88 | KIF11 (0.46) | KIF11SLC6A11SLC6A1KCNH2MEN1 | |
| SCHEMBL29194837 | 0.88 | KIF11 (0.46) | KIF11SLC6A11SLC6A1KCNH2MEN1 | |
| SCHEMBL29194795 | 0.88 | KIF11 (0.46) | KIF11SLC6A11SLC6A1KCNH2MEN1 | |
| SCHEMBL18803715 | 0.86 | KIF11 (0.52) | KIF11SLC6A11SLC6A1KCNH2CA4 | |
| SCHEMBL14879264 | 0.86 | KIF11 (0.52) | KIF11SLC6A11SLC6A1KCNH2CA4 | |
| SCHEMBL3996218 | 0.86 | KIF11 (0.49) | KIF11SLC6A11SLC6A1KCNH2CA4 | |
| SCHEMBL27989498 | 0.86 | KIF11 (0.63) | KIF11SLC6A1 | |
| SCHEMBL10022830 | 0.83 | KIF11 (0.49) | KIF11SLC6A11SLC6A1KCNH2CA4 | |
| SCHEMBL2490410 | 0.83 | SLC6A11 (0.50) | KIF11SLC6A11SLC6A1KCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117916374-A | Oligonucleotide-based delivery vehicles for oligonucleotide agents and methods of use thereof | 中美瑞康核酸技术(南通)研究院有限公司 | 2024-04-19 | — | — | CN | claimed |
| US-20030129589-A1 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. | 2003-07-10 | — | — | US | claimed |
| US-20020042112-A1 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. | 2002-04-11 | — | — | US | claimed |
| EP-0954612-A2 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998020166-A2 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | claimed |
| CN-117916374-A | Oligonucleotide-based delivery vehicles for oligonucleotide agents and methods of use thereof | 中美瑞康核酸技术(南通)研究院有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-1457496-B1 | High density immobilization of nucleic acids | SEQUENOM INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-7771929-B2 | Tag library compounds, compositions, kits and methods of use | MONOGRAM BIOSCIENCES, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1296143-B1 | Mass spectrometric detection of polypeptides | SEQUENOM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2009049007-A2 | COMPOSITIONS, METHODS AND SYSTEMS FOR RAPID IDENTIFICATION OF PATHOGENIC NUCLEIC ACIDS | MAGELLAN BIOSCIENCES, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| US-7501251-B2 | DNA diagnostics based on mass spectrometry | SEQUENOM, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20090023150-A1 | DNA Diagnostics Based on Mass Spectrometry | SEQUENOM, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-6322970-B1 | DIAGNOSING GENETIC OR CHROMOSOMAL DISORDERS; IN VITRO TRANSCRIPTION AND TRANSLATION; SEQUENCE DETERMINATION | SEQUENOM, INC. | 2001-11-27 | — | — | US | disclosed |
| WO-2001083502-A1 | TAG LIBRARY COMPOUNDS, COMPOSITIONS, KITS AND METHODS OF USE | ACLARA BIOSCIENCES, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-1010008-A2 | MASS SPECTROMETRIC DETECTION OF POLYPEPTIDES | SEQUENOM, INC. (US) | 2000-06-21 | — | — | EP | disclosed |
| EP-0954612-A2 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0937096-A2 | HIGH DENSITY IMMOBILIZATION OF NUCLEIC ACIDS | SEQUENOM, INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1999012040-A2 | MASS SPECTROMETRIC DETECTION OF POLYPEPTIDES | SEQUENOM, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| WO-1998020166-A2 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| WO-1998020020-A2 | HIGH DENSITY IMMOBILIZATION OF NUCLEIC ACIDS | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042112-A1 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | DNA2, DDB1, DNMT3A | KIF11 1143/4885SLC6A11 3886/4885SLC6A1 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.